MedTrace Logo

Performance Evaluation of the Micromedic BRONJ Risk Assessment in Vitro Diagnostic Assay

NCT02218554 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2014-08-18

No results posted yet for this study

Summary

To evaluate the performance of the Micromedic BRONJ Risk Assessment in vitro assay (the "BRONJ Assay") in identifying Multiple Myeloma (MM) and/or other cancer subjects at risk for developing Bisphosphonate-related Osteonecrosis of the Jaw (BRONJ) following intravenous (IV) administration of Bisphosphonates (BP).

Conditions

  • Bisphosphonate-related Osteonecrosis of the Jaw

Interventions

GENETIC

BRONJ

collection of the blood sample from the subject for evaluation of the Micromedic BRONJ Risk Assessment in vitro Diagnostic Assay

Sponsors & Collaborators

  • Micromedic Technologies Ltd

    lead INDUSTRY

Principal Investigators

  • Noam Yarom, Dr. · Sheba MC

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02218554 on ClinicalTrials.gov